A retrospective medical chart review study of dolutegravir-based two-drug-regimens for the treatment of HIV-1 patients
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Dolutegravir/lamivudine (Primary) ; Dolutegravir/rilpivirine (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms TANDEM
Most Recent Events
- 07 Sep 2022 New trial record
- 02 Aug 2022 Results presented at the 24th International AIDS Conference